Smith Brendan
Known title: Chief Financial OfficerCIK: 0001857492
Associated companies
Transaction History
| CRSP | ▼ Sell | Tax Withholding | 1,392 | $67K | 2/21/2023 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 3,825 | — | 2/18/2023 | View on chart |
| CRSP | ▼ Sell | Tax Withholding | 1,111 | $62K | 10/17/2022 | View on chart |
| CRSP | ▲ Buy | Option Exercise | 3,750 | — | 10/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
CRISPR Therapeutics to Share New Data at AHA and ACR 2026
CRISPR Therapeutics announced it will present late-breaking data at the American Heart Association and American College of Rheumatology conferences in 2026. These upcoming presentations are key events for the company, as they will provide new clinical insights into its treatments for heart and autoimmune conditions. The stock is currently trading near its 52-week low, making these data releases a significant factor for investors watching the company's progress.
CRISPR Therapeutics to Share New Data at AHA and ACR 2026. CRISPR Therapeutics announced it will present late-breaking data at the American Heart Association and American College of Rheumatology conferences in 2026. These upcoming presentations are key events for the company, as they will provide new clinical insights into its treatments for heart and autoimmune conditions. The stock is currently trading near its 52-week low, making these data releases a significant factor for investors watching the company's progress.